245 related articles for article (PubMed ID: 15751095)
1. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis.
Yokota S; Miyamae T; Imagawa T; Iwata N; Katakura S; Mori M; Woo P; Nishimoto N; Yoshizaki K; Kishimoto T
Arthritis Rheum; 2005 Mar; 52(3):818-25. PubMed ID: 15751095
[TBL] [Abstract][Full Text] [Related]
2. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study.
Nishimoto N; Yoshizaki K; Maeda K; Kuritani T; Deguchi H; Sato B; Imai N; Suemura M; Kakehi T; Takagi N; Kishimoto T
J Rheumatol; 2003 Jul; 30(7):1426-35. PubMed ID: 12858437
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
Choy EH; Isenberg DA; Garrood T; Farrow S; Ioannou Y; Bird H; Cheung N; Williams B; Hazleman B; Price R; Yoshizaki K; Nishimoto N; Kishimoto T; Panayi GS
Arthritis Rheum; 2002 Dec; 46(12):3143-50. PubMed ID: 12483717
[TBL] [Abstract][Full Text] [Related]
4. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.
Nishimoto N; Yoshizaki K; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Hashimoto J; Azuma J; Kishimoto T
Arthritis Rheum; 2004 Jun; 50(6):1761-9. PubMed ID: 15188351
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate.
Ruperto N; Murray KJ; Gerloni V; Wulffraat N; de Oliveira SK; Falcini F; Dolezalova P; Alessio M; Burgos-Vargas R; Corona F; Vesely R; Foster H; Davidson J; Zulian F; Asplin L; Baildam E; Consuegra JG; Ozdogan H; Saurenmann R; Joos R; Pistorio A; Woo P; Martini A;
Arthritis Rheum; 2004 Jul; 50(7):2191-201. PubMed ID: 15248217
[TBL] [Abstract][Full Text] [Related]
6. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.
Woo P; Southwood TR; Prieur AM; Doré CJ; Grainger J; David J; Ryder C; Hasson N; Hall A; Lemelle I
Arthritis Rheum; 2000 Aug; 43(8):1849-57. PubMed ID: 10943876
[TBL] [Abstract][Full Text] [Related]
7. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
Zeft A; Hollister R; LaFleur B; Sampath P; Soep J; McNally B; Kunkel G; Schlesinger M; Bohnsack J
J Clin Rheumatol; 2009 Jun; 15(4):161-4. PubMed ID: 19363453
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis.
Horneff G; Ebert A; Fitter S; Minden K; Foeldvari I; Kümmerle-Deschner J; Thon A; Girschick HJ; Weller F; Huppertz HI
Rheumatology (Oxford); 2009 Aug; 48(8):916-9. PubMed ID: 19483091
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
Lequerré T; Quartier P; Rosellini D; Alaoui F; De Bandt M; Mejjad O; Kone-Paut I; Michel M; Dernis E; Khellaf M; Limal N; Job-Deslandre C; Fautrel B; Le Loët X; Sibilia J; ;
Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302
[TBL] [Abstract][Full Text] [Related]
10. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
[TBL] [Abstract][Full Text] [Related]
11. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement.
Woo P; Wilkinson N; Prieur AM; Southwood T; Leone V; Livermore P; Wythe H; Thomson D; Kishimoto T
Arthritis Res Ther; 2005; 7(6):R1281-8. PubMed ID: 16277681
[TBL] [Abstract][Full Text] [Related]
12. High dose, alternate day corticosteroids for systemic onset juvenile rheumatoid arthritis.
Kimura Y; Fieldston E; Devries-Vandervlugt B; Li S; Imundo L
J Rheumatol; 2000 Aug; 27(8):2018-24. PubMed ID: 10955346
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis.
Céspedes-Cruz A; Gutiérrez-Suárez R; Pistorio A; Ravelli A; Loy A; Murray KJ; Gerloni V; Wulffraat N; Oliveira S; Walsh J; Penades IC; Alpigiani MG; Lahdenne P; Saad-Magalhães C; Cortis E; Lepore L; Kimura Y; Wouters C; Martini A; Ruperto N;
Ann Rheum Dis; 2008 Mar; 67(3):309-14. PubMed ID: 17875547
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
Prince FH; Twilt M; ten Cate R; van Rossum MA; Armbrust W; Hoppenreijs EP; van Santen-Hoeufft M; Koopman-Keemink Y; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2009 May; 68(5):635-41. PubMed ID: 18413443
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.
Lovell DJ; Reiff A; Jones OY; Schneider R; Nocton J; Stein LD; Gedalia A; Ilowite NT; Wallace CA; Whitmore JB; White B; Giannini EH;
Arthritis Rheum; 2006 Jun; 54(6):1987-94. PubMed ID: 16732547
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of etanercept in the treatment of juvenile idiopathic arthritis].
de Inocencio Arocena J; Merino Muñoz R; Alvarez Madrid C; García-Consuegra Molina J
An Pediatr (Barc); 2009 Apr; 70(4):354-61. PubMed ID: 19324597
[TBL] [Abstract][Full Text] [Related]
17. The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis.
Frosch M; Ahlmann M; Vogl T; Wittkowski H; Wulffraat N; Foell D; Roth J
Arthritis Rheum; 2009 Mar; 60(3):883-91. PubMed ID: 19248102
[TBL] [Abstract][Full Text] [Related]
18. Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial.
Brinkman DM; de Kleer IM; ten Cate R; van Rossum MA; Bekkering WP; Fasth A; van Tol MJ; Kuis W; Wulffraat NM; Vossen JM
Arthritis Rheum; 2007 Jul; 56(7):2410-21. PubMed ID: 17599770
[TBL] [Abstract][Full Text] [Related]
19. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis.
Kimura Y; Pinho P; Walco G; Higgins G; Hummell D; Szer I; Henrickson M; Watcher S; Reiff A
J Rheumatol; 2005 May; 32(5):935-42. PubMed ID: 15868633
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]